Shannon S Zhang

Clinical Associate, Medicine
School of Medicine

Molecularly targeted therapies, immunotherapy, precision oncology, circulating tumor DNA, benign hematology, malignant hematology, solid cancers

UCI Health Profile

Linkedin Profile

Distinction in Research, University of Arizona, 2020
Distinction in Community Service, University of Arizona, 2020

2026-Present
Clinical Associate
Department of Medicine, Hematology and Oncology
University of California, Irvine

Gold Medal for a Poetry Anthology, 24th International Latino Book Awards Ceremony, 2022
Outstanding Medical Student in Hematology and Oncology, 2020
University of Arizona Commitment to Underserved People (CUP) Leadership Award, 2018
UCSD Research Scholar Award, 2015
UCSD Dean’s Honors List, Provost Honors, 2013-2014
UCI Campuswide Honors Program, 2011-2013

Dr. Shannon Zhang is a UCI Health hematologist and medical oncologist devoted to providing high quality, evidence-based and compassionate care to her patients.

A San Diego native, Zhang earned her bachelor’s and master’s degrees from the UC San Diego, where she studied cancer immunotherapy and graduated with a Research Scholar Award. She earned her medical degree from the University of Arizona College of Medicine, Tucson, graduating with a Distinction in Research and Distinction in Community Service while receiving the division award for outstanding medical student in hematology and oncology. She completed her internal medicine residency and hematology/oncology fellowship training at the UC Irvine.

During training, Zhang authored more than 20 publications in lung cancer, head and neck cancer and colorectal cancer. She has presented her work at national conferences including International Association for the Study of Lung Cancer, American College of Physicians, and Society of General Internal Medicine. Outside of medicine, she enjoys trying new cooking and baking recipes, traveling with her husband, and Pilates.

Zhang S. (2022). Grateful for Time. Doctor Poets & Other Healers – COVID in Their Own Words. Golden Foothills Press.

Zhang S, Hasan N, Han J, Kroening G, Jutric Z, Afsari A, Attarian S, Valerin J. (2025). A Camouflaging Mystery: Solid-Tubulocystic Variant of Intrahepatic Cholangiocarcinoma. Human Pathology Reports. 42: 300797.

Zhang S, Qiao J. (2025). An Atypical Presentation of Catastrophic Antiphospholipid Syndrome with Refractoriness to Treatment. Blood Coagulation & Fibrinolysis. 36(3): 101-107.

Zhang S, Wang S, Arter A. (2024). Emotional Distress: The Hidden Barrier to Immunotherapy Success in Advanced Non-Small Cell Lung Cancer. Lung Cancer Targets and Therapy. 14(5): 1877–1881.

Triphuridet N, Zhang SS, Nagasaka M, Gao Y, Zhao JJ, Syn NL, Hanaoka T, Ou SI, Shum E. (2023). Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. JTO. 18(6):698-717.

Zhang SS, Ou SI. (2022). Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, EGFR Exon 20 Insertion, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs? Lung Cancer: Targets and Therapy. 13: 67-73.

Zhang SS, Lee JK, Tukachinsky H, Schrock AB, Nagasaka M, Ou SI. (2022). A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature. JTO Clin Res Rep. 3(9): 100387.

Zhang SS, Ou SI. (2022). Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. Lung Cancer: Targets and Therapy. 13: 23-31.

Brazel D, Zhang S, Nagasaka M. (2022). Spotlight on Tepotinib and Capmatinib for Non-small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer: Targets and Therapy. 13: 33-45.

Nagasaka M, Balmanoukian AS, Madison R, Zhang SS, Klempner SJ, Ou S. (2022). Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/T790M/G796S) in cis. Lung Cancer. 164: 52-55.

Zhang S, Brazel D, Kumar P, Schafer LN, Eidenschink B, Senthil M, Dayyani F. (2021). Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. Journal of Gastrointestinal Oncology. 12(6): 2643-2652.

Zhang S, Nagasaka M. (2021). Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy. 12: 115-122.

Zhang S, Zhu VW. (2021). Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. Lung Cancer: Targets and Therapy. 12: 61-65.

Zhang SS, Nagasaka M, Zhu VW, Ou S. (2021). Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer. 158: 126-136.

Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou S, Bauer KA, Nagasaka M. (2021). Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 157: 147-155.

Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou S, Christensen JG, Janne PA, Aguirre AJ. (2021). Acquired Resistance to KRASG12C Inhibition in Cancer. NEJM. 384: 2382-2393.

Ou S, Xiu J, Nagasaka M, Xia B, Zhang SS, Zhang Q, Swensen JJ, Spetzler D, Korn WM, Zhu VW, Liu SV. (2021). Identification of Novel CDH1-NRG2alpha and F11R-NRG2alpha Fusions in NSCLC Plus Additional Novel NRG2alpha Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. Journal of Thoracic Oncology. 2(2): 100132.

Zhang S, Charlton C, Amaraneni A, Maher K. (2019). A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain. Case Reports in Hematology. 2019. 2674359.

Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE. (2017). Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2(18): e93397.

Shinchi H, Crain B, Yao S, Chan M, Zhang SS, Ahmadiiveli A, Suda Y, Hayashi T, Cottam HB, Carson DA. (2015). Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjugate Chemistry. 26(8): 1713-1723.

Zhu VW, Zhang SS, Zhang J, Swensen J, Xiu J, Ou S. (2021). Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib. Journal of Thoracic Oncology. 16(7): 51-54.

Zhang S, Carson DA. (2016). Anti-tumor effects in head and neck cancer in response to toll-like receptor activation, checkpoint inhibition, and chemotherapy. ProQuest Dissertations Publishing.

American Society of Clinical Oncology

American Society of Hematology

American Medical Women’s Association

Hematology and Oncology (IM)

Link to this profile
https://faculty.uci.edu/profile/?facultyId=7395

Last updated
09/16/2026